Michael Hennig

leadXpro AG, Switzerland

Title: Cryo-em and x-ray free electron laser enabled structure based drug discovery on challenging membrane protein targets

---

Biography

Michael Hennig studied Physics and Biochemistry, received the Ph.D. in structural biology at EMBL Hamburg, and the Charité, Humboldt University Berlin, Germany. It followed two years postdoc work at the Biozentrum, University of Basel, Switzerland. He is author of more than 80 scientific peer reviewed paper and, since 2011, guest professor in structural biology at the University of Basel. He worked 20 years in pharmaceutical industry at Roche, Basel, Switzerland in various positions and finally Global Head and Principle Leader of discovery technologies with responsibility for structure-based drug discovery, protein science, assay development and HTS, Roche corporate compound library, stem cell platform and analytical physical methods. In 2015, he co-founded leadXpro, a corporation dedicated to structure-based drug discovery for membrane protein targets (GPCR’s, Ion-channels, Transporter) and utilizing most advanced technologies such as the X-ray free electron laser (at PSI, SwissFEL) and cryo-electron microscopy (at University of Basel, cryo-EM).

Abstract

Structure Based Drug Design, Drug Discovery, Drug Targets